10,819 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by Syon Capital LLC

Syon Capital LLC bought a new position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 10,819 shares of the company's stock, valued at approximately $468,000.

Several other hedge funds have also added to or reduced their stakes in SRRK. FMR LLC increased its position in shares of Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after acquiring an additional 3,439,215 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Scholar Rock by 7.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock worth $401,231,000 after buying an additional 629,315 shares during the period. Vanguard Group Inc. increased its stake in shares of Scholar Rock by 17.6% during the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after buying an additional 708,817 shares during the period. Marshall Wace LLP lifted its stake in Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the period. Finally, Norges Bank bought a new stake in Scholar Rock in the fourth quarter valued at $86,043,000. 91.08% of the stock is owned by institutional investors.

Insider Buying and Selling at Scholar Rock

In other news, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at $3,966,108.90. The trade was a 56.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the sale, the insider now owns 111,084 shares of the company's stock, valued at approximately $4,154,541.60. The trade was a 38.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 255,231 shares of company stock worth $9,220,236. 13.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock currently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Stock Up 1.2 %

SRRK traded up $0.40 during midday trading on Wednesday, reaching $33.17. The company's stock had a trading volume of 310,402 shares, compared to its average volume of 1,249,795. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average is $32.51 and its 200-day moving average is $35.74. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of -14.11 and a beta of 0.56.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.